The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD

The Effect of Alogliptin Combined With Pioglitazone and Metformin Hydrochloride Tablets on Glucose and Lipid Metabolism and Islet Function in Patients With Type 2 Diabetes Mellitus Complicated With Metabolic Dysfunction-associated Fatty Liver Disease

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07289750

Enrollment

Registered

2025-12-17

Start date

2026-05-01

Completion date

2027-08-31

Last updated

2026-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MAFLD, T2DM

Keywords

T2DM, MAFLD

Brief summary

To compare the efficacy and safety of the combination of alogliptin and actoplus met with that of actoplus met alone in improving the glucose and lipid metabolism and pancreatic function in T2DM patients complicated with MAFLD.

Interventions

DRUGalogliptin and actoplus met

combination of alogliptin and actoplus met

DRUGactoplus met

actoplus met

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of T2DM * Clinical diagnosis of MAFLD * HbA1c: 6.5-9.5% * BMI: 19-35 kg/m2 * No hypoglycemic drugs or insulin have been used within half a year

Exclusion criteria

* Severe infections, surgeries and other emergency * Other types of diabetes * Severe cardiovascular, brain, liver and kidney disorders * Malignant tumor

Design outcomes

Primary

Measure	Time frame
hemoglobin A1c	6 months of treatment

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026